- Conditions
- Delayed Function of Renal Transplant
- Interventions
- Eculizumab, Placebo
- Drug
- Lead sponsor
- Schroppel, Bernd, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality, Morbidity;Newborn, Maternal Injury, Preeclampsia Severe
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Paroxysmal Hemoglobinuria, Nocturnal
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Paroxysmal Hemoglobinuria, Nocturnal
- Interventions
- eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 14
- States / cities
- Stanford, California • Hartford, Connecticut • Weston, Florida + 10 more
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Ravulizumab, Eculizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Whittier, California • Fort Worth, Texas
- Conditions
- Kidney Transplant
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hemoglobinuria, Paroxysmal
- Interventions
- eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 16
- States / cities
- Duarte, California • Los Angeles, California • San Diego, California + 12 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fresno, California + 29 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Eculizumab, Saline
- Drug
- Lead sponsor
- Philip J. Rosenfeld, MD, PhD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Danicopan, Placebo, C5 Inhibitor
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Weston, Florida • Chicago, Illinois + 4 more
- Conditions
- Dense Deposit Disease, Membranoproliferative Glomerulonephritis
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Coversin
- Drug
- Lead sponsor
- AKARI Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Refractory Generalized Myasthenia Gravis
- Interventions
- Eculizumab, Placebo
- Biological · Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more
- Conditions
- Thrombocytopenia, Alloimmune Platelet Refractoriness
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria, PNH
- Interventions
- Danicopan, Soliris/Ultomiris
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Standard of care treatment, eculizumab
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 6,061 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End Stage Liver Disease
- Interventions
- Eculizumab, No intervention
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Myasthenia Gravis
- Interventions
- eculizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Orange, California • Sacramento, California + 17 more
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more
- Conditions
- Kidney Transplant
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Mark Stegall
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hemoglobinuria, Paroxysmal
- Interventions
- eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Stanford, California • Hartford, Connecticut + 15 more
- Conditions
- Hemoglobinuria, Paroxysmal
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atypical Hemolytic-Uremic Syndrome
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Hackensack, New Jersey • Corpus Christi, Texas + 1 more